___

• 1. Paner GP, Aron M, Hansel DE, Amin MB. Non-epithelial neoplasms of the prostate. Histopathology 2012;60(1):166–86.
• 2. Ro JY, Amin MB, Kim KR, Ayala AG. Prostate and seminal vesicles. In: Fletcher CD, editor. Diagnostic Histopathology of Tumors, 3rd ed. Philadelphia: Churchill Livingstone Elsevier;2007. p. 798–800.
• 3. Epstein JI. The Prostate and Seminal Vesicles. In: Mills SE, editor. In: Diagnostic Surgical Pathology. 4th ed. New York: Raven Press 2004. p. 2083–132.
• 4. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157(6):1769–75.
• 5. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL. Tumors of the Prostate Gland, Seminal Vesicle, Male Urethra, and Penis. 3rd ed. Vol. 28. Washington, DC: Armed Forces Institute of Pathology;2000 p. 1–344.
• 6. Srigley JR, Dardick I, Hartwick RW, Klotz L. Basal epithelial cells of human prostate gland are not myoepithelial cells. A comparative immunohistochemical and ultrastructural study with the human salivary gland. Am J Pathol 1990;136(4):957–66.
• 7. Fraggetta F, Pepe P, Giunta ML, Aragona F. Primary high grade sarcoma of the specialised prostatic stroma: a case report with clinico-pathological considerations. Pathologica 2008;100(6):482–4.
• 8. Stout AP. Mesenchymoma, the Mixed Tumor of Mesenchymal Derivatives. Ann Surg 1948;127(2):278–90.
• 9. Brady MS, Perino G, Tallini G, Russo P, Woodruff JM. Malignant mesenchymoma. Cancer 1996;77(3):467–73.
• 10.Newman PL, Fletcher CD. Malignant mesenchymoma. Clinicopathologic analysis of a series with evidence of low-grade behaviour. Am J Surg Pathol 1991;15(7):607– 14.
• 11.Adachi T, Oda Y, Sakamoto A, Terashi T, Tamiya S, Hachitanda Y, et al. Prognostic factors in the socalled malignant mesenchymoma: a clinicopathological and immunohistochemical analysis. Oncol Rep 2003;10(4):803–11.